BioNexus Gene Lab Corp. has announced the regional deployment of its VitaGuard™ Minimal Residual Disease (MRD) platform, marking a significant expansion across Southeast Asia. The company is moving forward with initial rollouts in key medical hubs, aiming to establish routine MRD monitoring for solid tumor indications. To support this expansion, BioNexus has established Fidelion Diagnostics Pte. Ltd. as the commercialization vehicle outside China and has actively recruited experienced personnel. The initiative also includes partnerships with regional healthcare providers to integrate VitaGuard™ into standard care, positioning BioNexus to address the growing demand for affordable, AI-enhanced precision oncology in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-000610), on February 03, 2026, and is solely responsible for the information contained therein.